Carlos E de Andrea
Overview
Explore the profile of Carlos E de Andrea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1056
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garate-Soraluze E, Serrano-Mendioroz I, Fernandez-Rubio L, de Andrea C, Barrio-Alonso C, Herrero C, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39933836
Background: Ionizing radiation (IR) is a double-edged sword for immunotherapy as it may have both immunosuppressive and immunostimulatory effects. The biological effects of IR on the tumor microenvironment (TME) are...
2.
de Andrea C, Lopez-Janeiro A, Hogendoorn P
J Clin Pathol
. 2025 Feb;
PMID: 39915066
Several types of tumours and tumour-like lesions are recognised. Their classification is based mainly on the cell or tissue differentiation pathway found within the lesion. Not all tumour cells in...
3.
Senent Y, Remirez A, Reparaz D, Llopiz D, Celias D, Sainz C, et al.
Cancer Immunol Res
. 2024 Dec;
13(3):384-399.
PMID: 39666368
The precise mechanisms by which the complement system contributes to the establishment of an immunosuppressive tumor microenvironment and promotes tumor progression remain unclear. In this study, we investigated the expression...
4.
Eguren-Santamaria I, Fernandez de Pierola E, Camps G, Martin-Munoz P, Campos M, Cuculescu D, et al.
J Immunother Cancer
. 2024 Sep;
12(9).
PMID: 39244214
Background: Immunodeficient mice engrafted with peripheral blood mononuclear cells (PBMCs) are models to study new cancer immunotherapy agents. However, this approach is associated with xenograft-versus-host disease (xGVHD), which starts early...
5.
Aguilera-Buenosvinos I, Martinez-Gonzalez M, Romanos-Nanclares A, Sanchez-Bayona R, de Andrea C, Dominguez L, et al.
J Physiol Biochem
. 2024 Sep;
PMID: 39235717
An association between type 2 diabetes (T2D) and breast cancer risk has been reported. This association can be potentially explained by alteration of the insulin/IGF system. Therefore, we aimed to...
6.
de Dios O, Ramirez-Gonzalez M, Gomez-Soria I, Segura-Collar B, Manosalva J, Megias D, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39214651
Background: Activating and inhibitory receptors of natural killer (NK) cells such as NKp, NKG2, or CLEC are highly relevant to cold tumors including glioblastoma (GBM). Here, we aimed to characterize...
7.
Lopez Janeiro A, Wong E, Jimenez-Sanchez D, Ortiz de Solorzano C, Lozano M, Teijeira A, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38821717
Introduction: The tissue immune microenvironment is associated with key aspects of tumor biology. The interaction between the immune system and cancer cells has predictive and prognostic potential across different tumor...
8.
Teijeira A, Garasa S, Ochoa M, Sanchez-Gregorio S, Gomis G, Luri-Rey C, et al.
Clin Cancer Res
. 2024 Apr;
30(18):4131-4142.
PMID: 38630754
Purpose: Patients with cancer frequently undergo radiotherapy in their clinical management with unintended irradiation of blood vessels and copiously irrigated organs in which polymorphonuclear leukocytes circulate. Following the observation that...
9.
Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, Garcia Garcia Y, et al.
Clin Cancer Res
. 2023 Aug;
30(1):176-186.
PMID: 37527007
Purpose: The aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the changes with the clinical...
10.
Nassiri F, Patil V, Yefet L, Singh O, Liu J, Dang R, et al.
Nat Med
. 2023 May;
29(6):1370-1378.
PMID: 37188783
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the...